Tara Lifescience Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-07-2024
- Paid Up Capital ₹ 0.10 M
as on 18-07-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 20.08%
(FY 2022)
- Profit -3.03%
(FY 2022)
- Ebitda 24.15%
(FY 2022)
- Net Worth 57.88%
(FY 2022)
- Total Assets 47.61%
(FY 2022)
About Tara Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhraman Marliwar, Bhushan Marliwar, and Bhupendra Marliwar serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PTC293806
- Company No.
293806
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Apr 2017
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Tara Lifescience?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhraman Marliwar  | Director | 12-Apr-2017 | Current |
| Bhushan Marliwar | Director | 12-Apr-2017 | Current |
| Bhupendra Marliwar | Director | 12-Apr-2017 | Current |
Financial Performance of Tara Lifescience.
Tara Lifescience Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.08% increase. The company also saw a slight decrease in profitability, with a 3.03% decrease in profit. The company's net worth Soared by an impressive increase of 57.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tara Lifescience?
In 2022, Tara Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Taraasian Drugs Private LimitedActive 7 years 5 monthsBhraman Marliwar, Bhushan Marliwar and 1 more are mutual person
- 5 Milligram Pharmaceuticals Private LimitedActive 1 year 6 months
Bhushan Marliwar and Bhupendra Marliwar are mutual person
- Signity Pharmaceuticals Private LimitedActive 14 years 3 months
Bhupendra Marliwar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Tara Lifescience?
Unlock and access historical data on people associated with Tara Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tara Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tara Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
